Advanced searches left 3/3

Lung Cancer - DOAJ

Summarized by Plex Scholar
Last Updated: 15 June 2022

* If you want to update the article please login/register

Preliminary Evaluation of a Citizen Scientist Educational Curriculum Aimed at Engaging Black Men in Lung Cancer Early Detection Screening

"This essay describes an educational scheme that encourages African American men to participate as citizen scientists and future research partners in a lung cancer screening program. " In addition, we review lessons learned in the engagement of African American men as CS in community-based lung-health equity studies. Five group-based sessions were delivered through zoom in the CS educational program. The educational curriculum was expanded from the University of Florida Citizen Scientist program and tailored to address lung health and African American males' cultural experiences. The CS educational program was completed by eight African American men. Seven participants also obtained additional human subject research accreditation. According to the study's findings, it was possible to offer an online citizen science training course to prepare participants to participate in a lung cancer screening service for African American men.

Source link: https://doi.org/10.1177/15579883221099417


Real-world experience with capmatinib in exon 14-mutated non-small cell lung cancer (RECAP): a retrospective analysis from an early access program

Patients with non-small cell lung cancer presenting with mesenchymalu2013epithelial transition exon 14 skipping mutation have unfavorable prognosis with standard treatments, according to the author. Capmatinib, a selective MET inhibitor, showed promising results in this patient group in early trials. Methods: We conducted a retrospective, international, multicenter efficacy, and safety study in patients with NSCLC treated with capmatinib in an early access program between March 2019 and December 2021. Results: The results of 81 patients with advanced MET exon 14 mutated NSCLC treated with capmatinib in first- or later-line therapy were reviewed. The objective response rate to capmatinib was 58% in treatment-nau00efve and 50% in pretreated patients, respectively. The intracranial ORR in patients with confirmed brain metastases was 46%. Capmatinib demonstrated persistent systemic and intracranial safety in patients with a MET exon 14 skipping mutation, as well as a streamlined safety profile, according to the researchers.

Source link: https://doi.org/10.1177/17588359221103206


An 8-Gene Signature for Classifying Major Subtypes of Non-Small-Cell Lung Cancer

"Motivation: The exact diagnosis of non-small cell lung cancer's key subtypes, lung adenocarcinoma, and lung squamous cell carcinoma in non-small-cell lung cancer is of utmost importance, especially because some drugs are subtype-specific. " Our aim: We're looking for the right candidate after an expression-based system that consistently recommends a large number of candidate gene signatures and selects the right candidate. By applying this technique to a training set, the most appropriate gene signature was found by considering close to 765 billion candidate signatures. When tested using 34 independent gene expression datasets containing 2556 adenocarcinoma and 1630 squamous cell carcinoma samples, the signature displayed a high overall prediction accuracy of 0. 936. Our signature was also more accurate in terms of overall accuracy and particularly accuracy in describing lung squamous cell carcinoma. Conclusions: Our signature is both simple to use and accurate, regardless of the method used to create the gene expression profiles. ".

Source link: https://doi.org/10.1177/11769351221100718


Population pharmacokinetics of mobocertinib in healthy volunteers and patients with non–small cell lung cancer

"Abstract Mobocertinib is a tissue kinase inhibitor that has been approved for use of patients with locally advanced or metastatic non-u2010small cell lung cancer with epidermal growth factor receptor gene exon 20 insertion mutations whose disease has deteriorated on or after platinum-based chemotherapy. " Two compartments for mobocertinib with absorbtion through three compartments for AP32960, two compartments for AP32960, and one compartment for AP32914 were well-defined in a joint semimechanistic scheme. In the final model, structural covariates were included as structural covariates, with apparent oral clearance of all three moieties and apparent central volume of distribution for mobocertinib. No clinically significant differences in mobocertinib PK were found based on age, race, sex, body height, mild to moderate hepatitis impairment, or mildu2010to-u2010moderate renal impairment, indicating that no dosage adjustment is required in patients with mNSCLC.

Source link: https://doi.org/10.1002/psp4.12785


Leptomeningeal Metastatic L858R EGFR-mutant Lung Cancer: Prompt Response to Osimertinib in the Absence of T790M-mutation and Effective Subsequent Pulsed Erlotinib

"However, therapy options for LMC related to metastatic epidermal growth factor receptor mutant lung adenocarcinoma are growing," the author says. We've got a 52-year-old male patient with metastatic non-small-cell lung cancer. The patient was found to have an L858R mutation in exon 21 of the EGFR gene. Although tissue biopsy revealed T790M mutations, osimertinib immediately triggered medical and radiological responses that lasted for five months. ".

Source link: https://doaj.org/article/fd54f6bed52c453ba12201c4c0b2720b


Lung Cancer with Brain Metastases Treated with Radiotherapy Followed by Bevacizumab Maintenance: A Case Report

"A serious prognosis is found in a patient with non-small cell lung cancer. " The primary goal of our investigation is to determine the extent of safety and efficacy of anti-vascular endothelial growth factor agents in the case of lung cancer with brain metastases.

Source link: https://doi.org/10.31729/jnma.7400


Dysbiosis of the Gut Microbiome Is Associated With Histopathology of Lung Cancer

"However, studies into the characteristics of the gut microbiome in different histopathology types of lung cancer remain scant. " Our analysis revealed that the classified cancer patients had particular intestinal flora characteristics, were lower density, and flora diversity in comparison to healthy people. Compared to the IA and MIA groups, the patients in the AAH/AIS group and HP group had relatively similar flora patterns. Lung cancer gut microbiota showed a decrease in short-chain fatty acids manufacturing and anti-inflammatory bacteria relative to healthy individuals, although other pathogenic bacteria such as proinflammatory or tumor-promoting bacteria were more prevalent in lung cancer patients. These results reveal new biomarkers for lung cancer diagnosis and prognostic evaluation, as well as the development of novel targeted therapeutic approaches for lung cancer prevention and treatment. http://www. clinicalTrials. gov] [NCT03244605].

Source link: https://doi.org/10.3389/fmicb.2022.918823


Beyond Crizotinib: A Systematic Review and Meta-Analysis of the Next-Generation ALK Inhibitors as First-Line Treatment for ALK-Translocated Lung Cancer

"BackgroundSecond and third-generation ALK inhibitors have recently been cleared for ALK-translocated lung cancer therapy, raising the first-line scenario. "Methods is a newspaper that publishes news about systematic phase III controlled trials in untreated advanced ALK-translocated lung cancer patients. " In total, seven randomized controlled trials met our inclusion criteria. Results were published in Stata software. Comparing the results of next-generation ALKIs and control therapy, the next-generation ALKIs dramatically improved progression-free survival, overall survival, disease control rate, any lesion, and quantitative lesions of central nervous system response rate compared to previous generations. The experimental and control groups' results were similar. ConclusionOur study revealed that next-generation ALKIs are the most commonly used first-line treatment option for ALK-translocated lung cancer.

Source link: https://doi.org/10.3389/fonc.2022.921854


Case report: pathological complete response in an IIIB non-small cell lung cancer patient after preoperative neoadjuvant nivolumab therapy combined with chemotherapy

"The neoadjuvant therapy approach for locally advanced non-small cell lung cancer is particularly effective in locally developed NSCLC, especially for locally advanced NSCLC that are still unresectable. " We hope that this representative medical record and literature review will give clinicians using immune checkpoint inhibitors to treat lung cancer some assistance. On April 27, 2020, a 50-year-old male patient was admitted to Zhongshan Hospital of Traditional Chinese Medicine after more than a month, owing to u201c coughing. u201d Right lower lung NSCLC with right hilar and mediastinal lymph node metastasis, according to the doctor. Lessons: The patient underwent thoracoscopic radical resection of the tumor in the right upper lung and postoperative pathology and postoperative pathology. This may be a way to treat more lung cancer patients in the future.

Source link: https://doi.org/10.1097/MD.0000000000029336


Effect of ulinastatin on the inflammatory response after video-assisted thoracic lobectomy in patients with lung cancer: a randomized controlled study

"The first-line treatment for lung cancer is surgical resection, and one-lung ventilation is the most common anesthesia management technique in lung surgery," the first-line treatment. During OLV, inflammatory cytokines are released in response to the lung tissue damage and promote local and contralateral lung disease through the systemic circulation. We designed a randomized, prospective study to see the effect of the urinary trypsin inhibitor ulinastatin on the inflammatory response after a video-assisted thoracic lobectomy in patients with lung cancer. ".

Source link: https://doi.org/10.1097/CM9.0000000000001937

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions